{
    "nct_id": "NCT06683365",
    "official_title": "A Phase I Study of the Feasibility and Safety of SuraL nervE Tissue Grafting to the Substantia nigrA in Patients With Synucleinopathies (LEAP)",
    "inclusion_criteria": "* Diagnosis of clinically established or clinically probable PD or MSA as defined by MDS criteria\n* Disease duration greater than 2 years\n* Age 40-75, inclusive\n* MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part III greater than or equal to 20 points but less than or equal to 35 points, off anti-parkinsonian medication for PD or MDS-Unified Multiple System Atrophy Rating Scale (UMSARS) less than or equal to 30 points off anti-parkinsonian medication\n* No MDS-UPDRS Part III score >3 on items 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.14 while off medication\n* Able and willing to undergo ioflupane/SPECT\n* Able to tolerate the surgical procedure\n* Able to undergo all planned assessments\n* Available access to the sural nerve\nHealthy volunteers allowed\nMust have minimum age of 40 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Previous PD surgery or intracranial surgery\n* Ongoing major medical or psychiatric disorder incl. depression and psychosis\n* Other concomitant treatment with neuroleptics\n* Typical, nonparkinsonian syndrome ioflupane/SPECT signal\n* Unable to undergo an MRI\n* An obstructed trajectory path to the substantia nigra\n* Significant microvascular disease\n* Use of anticoagulants other than aspirin\n* Female who is pregnant, lactating, or of child-bearing potential unwilling to use an adequate birth control method during the period of the study\n* Consent capacity will be assessed and determined during and throughout a participant's neuropsychological exam. A participant who experiences a decline in consent capacity prior to surgery, will be removed from the study by the PI. A decline in consent capacity after surgery will not result in the removal of the participant in the study.",
    "miscellaneous_criteria": ""
}